Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?
CONCLUSION: In our cohort, there were no differences between anti-TNFα trough levels, formation of anti-TNFα antibodies or inflammatory biomarkers among patients in combotherapy with azathioprine, irrespective of its dosage. In conclusion, our study suggests that maintaining therapeutic levels of anti-TNFα drugs without antibodies formation is feasible with lower doses of azathioprine, minimizing its side effects.
PMID: 32689833 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More News: Crohn's Disease | Gastroenterology | Humira | Inflammatory Bowel Disease | PET Scan | Remicade | Study | Ulcerative Colitis